WNK2 and cancer: In cancer cells with mutated receptor tyrosine kinases (RTKs) or oncogenes with kinase activity, growth is typically driven by the constitutive activation of downstream signaling cascades, such as the mitogen-activated protein kinase (MAPK) pathway [18].